UBS Group’s iShares Evolved U.S. Innovative Healthcare ETF IEIH Stock Holding History

UBS Group’s Portfolio IEIH Stock Details IEIH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,506	Closed	-$50K	–	11732
2022 Q2	$50K	Sell	1,506 -1,176	-44%	-$38.6K	﹤0.01%	5920
2022 Q1	$92K	Buy	2,682 +939	+54%	+$31.1K	﹤0.01%	5992
2021 Q4	$62K	Buy	1,743 +1,357	+352%	+$47.4K	﹤0.01%	6733
2021 Q3	$14K	Buy	+386	New	+$14K	﹤0.01%	7630
2021 Q2	–	Sell	-1,418	Closed	-$46K	–	10165
2021 Q1	$46K	Buy	1,418 +1,113	+365%	+$37K	﹤0.01%	6654
2020 Q4	$10K	Buy	+305	New	+$9.53K	﹤0.01%	7526

UBS Group's IEIH Position: Q3 2022 in Review

UBS Group sold out of iShares Evolved U.S. Innovative Healthcare ETF (IEIH) in Q3 2022, closing a stake of 1,506 shares — an estimated $50K sold.

UBS Group first reported a position in IEIH in Q4 2020 and held it in 6 quarters. The position peaked at $92K in Q1 2022. 0 funds tracked by Wall St. Rank hold IEIH as of Q3 2022.

UBS Group reported no remaining iShares Evolved U.S. Innovative Healthcare ETF position as of Q3 2022 after selling out during the quarter.
UBS Group sold 1,506 iShares Evolved U.S. Innovative Healthcare ETF shares in Q3 2022, an estimated $50K.
UBS Group first reported a position in iShares Evolved U.S. Innovative Healthcare ETF in Q4 2020 and held it in 6 quarters.
UBS Group's iShares Evolved U.S. Innovative Healthcare ETF position peaked at $92K in Q1 2022.
0 funds tracked by Wall St. Rank held iShares Evolved U.S. Innovative Healthcare ETF as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.